hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06358716 id: CEIC-3037 briefTitle: Glycaemic Index Determination in Oral Nutrition Supplements acronym: BEGINS overallStatus: RECRUITING date: 2024-04-15 date: 2024-07-15 date: 2024-08-15 date: 2024-04-10 date: 2024-04-10 name: Universitat de Lleida class: OTHER name: Lactalis briefSummary: The glycemic index is the ability of carbohydrates in foods to induce increases in blood glucose levels after consuming them. Based on the capacity for increasing blood glucose levels, foods can be classified as having a low, medium, or high glycemic index. This property is of interest in health and nutrition because it allows estimating the impact the food will have on postprandial glycemia, which may able better food selection in situations where adequate glycemic control is required, such as in individuals diagnosed with Diabetes Mellitus. The objective of this study is to determine the glycemic index of 9 formulations of complete oral nutrition supplements and classify them based on their glycemic response. conditions: Glucose Metabolism Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 15 type: ESTIMATED name: Complete Oral Nutrition Supplement 1 name: Complete Oral Nutrition Supplement 2 name: Complete Oral Nutrition Supplement 3 name: Complete Oral Nutrition Supplement 4 name: Complete Oral Nutrition Supplement 5 name: Complete Oral Nutrition Supplement 6 name: Complete Oral Nutrition Supplement 7 name: Complete Oral Nutrition Supplement 8 name: Complete Oral Nutrition Supplement 9 name: Glucose measure: Glycemic Index sex: ALL minimumAge: 21 Years maximumAge: 60 Years stdAges: ADULT facility: University of Lleida status: RECRUITING city: Lleida zip: 25198 country: Spain name: Jose Serrano, PhD role: CONTACT phone: 973702408 email: josecarlos.serrano@udl.cat name: Manuel Portero, PhD role: CONTACT phone: 973702408 email: manuel.portero@udl.cat lat: 41.61674 lon: 0.62218 hasResults: False
nctId: NCT06358703 id: P400 briefTitle: Impact of Acute iTTP Therapies on Long Term Neurologic and Cognitive Outcomes in iTTP Survivors acronym: NeST overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-05 date: 2028-05 date: 2024-04-10 date: 2024-04-10 name: US Thrombotic Microangiopathy Alliance class: OTHER briefSummary: 1. We expect to find that the silent cerebral infarct (SCI) rate is two fold higher in patients treated without caplacizumab. We also expect to find that the rate of mild and major cognitive impairment in patients treated with caplacizumab within 3 days of starting plasma exchange will be lower than patients treated without caplacizumab.
4. Based on studies in non-TTP populations, we expect to find that the rate of incident stroke over the period of follow up is at least 2 fold higher in patients that have SCI compared with patients who do not have SCI conditions: Immune Thrombotic Thrombocytopenia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 116 type: ESTIMATED name: Caplacizumab measure: Silent cerebral infarction measure: Cognitive impairment measure: Depression scores on BDI-II measure: SF-36 scores for quality of life measure: Patient reported cognitive performance sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: USTMA city: Groveport state: Ohio zip: 43125 country: United States name: Clare Martin role: CONTACT phone: 614-999-4900 email: Clare@ustma.org lat: 39.8784 lon: -82.88379 hasResults: False
nctId: NCT06358677 id: HCI171997 briefTitle: Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer acronym: FACE overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-07 date: 2029-07 date: 2024-04-10 date: 2024-04-17 name: University of Utah class: OTHER briefSummary: The goal of this clinical trial is to learn if using topical tretinoin will help patients with colorectal cancer who are experiencing an acneiform rash as a side effect of their treatment.
Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact. conditions: Metastatic Colon Cancer conditions: Metastatic Rectum Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomized, double-blind, split-face, phase II study of topical tretinoin prophylaxis for anti-EGFR treatment-induced skin toxicity in metastatic colorectal cancer. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Patients will apply topical tretinoin to one half of the face and topical moisturizer (placebo) to the other half of the face daily starting the day that anti-EGFR treatment is initiated. The sides of the face tretinoin and moisturizer are applied to will be randomized. Standardized photographs of the face will be obtained at screening and every two weeks from Week 1 Day 1 until after six weeks of treatment. Photographs will be graded by a dermatologist who will be blinded to treatment sidedness. Facial rash severity will be graded using a modified Investigators Global Assessment (IGA) score. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 25 type: ESTIMATED name: Topical Tretinoin name: Placebo measure: The maximum difference in modified Investigators Global Assessment (IGA) score between the treated and untreated sides of the face at any assessment. measure: Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE version 5.0 and the modified IGA), seriousness, duration, and relationship to study treatment. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huntsman Cancer Institute at University of Utah city: Salt Lake City state: Utah zip: 84112 country: United States lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06358664 id: Caffeine Vitrectomy briefTitle: Caffeine and Cataract After Pars Plana Vitrectomy overallStatus: RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-04-01 date: 2024-04-10 date: 2024-04-12 name: Vienna Institute for Research in Ocular Surgery class: OTHER briefSummary: Assessment of cataract development in patients with regular caffeine consumption and those without caffeine consumption after pars plana vitrectomy. conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 74 type: ESTIMATED name: Pars plana vitrectomy measure: Significant cataract formation at year 1 measure: Significant cataract formation at month 6 measure: Distance corrected visual acuity (DCVA) sex: ALL minimumAge: 18 Years maximumAge: 105 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital, Vienna status: RECRUITING city: Vienna zip: 1140 country: Austria name: Andreas Schlatter, MD role: CONTACT phone: +4391021 phoneExt: 57564 email: office@viros.at name: Christoph Leisser, MMD role: CONTACT phone: +4391021 phoneExt: 57564 email: office@viros.at lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06358651 id: PH94B-CL042 briefTitle: Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) acronym: PALISADE-3 overallStatus: RECRUITING date: 2024-03-28 date: 2025-06 date: 2026-06 date: 2024-04-10 date: 2024-04-10 name: VistaGen Therapeutics, Inc. class: INDUSTRY briefSummary: This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-3 and choose to enter the distinct open-label extension phase of the study. conditions: Social Anxiety Disorder studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 236 type: ESTIMATED name: Fasedienol Nasal Spray name: Placebo Nasal Spray measure: Subjective Units of Distress Scale (SUDS) measure: Global Impression Scale of Improvement (CGI-I) measure: Patient Global Impression of Change (PGI-C) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vistagen Clinical Site status: RECRUITING city: Oceanside state: California zip: 92056 country: United States lat: 33.19587 lon: -117.37948 facility: Vistagen Clinical Site status: RECRUITING city: Jacksonville state: Florida zip: 32256 country: United States lat: 30.33218 lon: -81.65565 facility: Vistagen Clinical Site status: RECRUITING city: Orlando state: Florida zip: 32801 country: United States lat: 28.53834 lon: -81.37924 facility: Vistagen Clinical Site status: RECRUITING city: New York state: New York zip: 10128 country: United States lat: 40.71427 lon: -74.00597 facility: Vistagen Clinical Site status: RECRUITING city: Memphis state: Tennessee zip: 38119 country: United States lat: 35.14953 lon: -90.04898 hasResults: False
nctId: NCT06358638 id: STUDY00000859 briefTitle: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY acronym: SUN-RAY overallStatus: RECRUITING date: 2024-04 date: 2044-09 date: 2054-09 date: 2024-04-10 date: 2024-04-10 name: Children's National Research Institute class: OTHER name: Alberta Children's Hospital name: The Hospital for Sick Children name: Levine Children's Hospital name: Ann & Robert H Lurie Children's Hospital of Chicago name: Nationwide Children's Hospital name: Children's Hospital at Montefiore name: Doris Duke Charitable Foundation name: Janssen Pharmaceuticals briefSummary: This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies. conditions: Sickle Cell Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Sickle cell patients, who have matched sibling donors with anti-donor RBC antibodies. primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Daratumumab name: Alemtuzumab name: Sirolimus name: Total Body Irradiation measure: To determine the event-free survival of children and adolescents with SCD undergoing nonmyeloablative HCT who received 4 doses of pre-HCT daratumumab for donor-directed red blood cell antibodies. measure: To evaluate changes in antibodies to red blood cell antigens pre and post exposure to daratumumab and HCT. measure: To characterize the safety of adding pre-HCT daratumumab to the conditioning regimen, as defined by adverse events grade 3 or greater. measure: To compare alemtuzumab levels, in mcg/mL, post-HCT among patients treated with daratumumab, with patients not treated with daratumumab on the SUN study. measure: To compare immune reconstitution among patients treated with daratumumab, with patients not treated with daratumumab on the SUN study. measure: To compare donor chimerism (lymphoid vs myeloid) post-HCT among patients treated with daratumumab, with patients not treated with daratumumab on the SUN study. sex: ALL minimumAge: 2 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Children's National Hospital status: RECRUITING city: Washington state: District of Columbia zip: 20010 country: United States name: Maryanne Odinakachukwu role: CONTACT phone: 202-476-2957 email: modinakach@childrensnational.org name: Robert Nickel role: PRINCIPAL_INVESTIGATOR name: David Jacobsohn role: SUB_INVESTIGATOR name: Anant Vatsayan role: SUB_INVESTIGATOR name: Blachy Dávila-Saldaña role: SUB_INVESTIGATOR name: Evelio Perez-Albuerne role: SUB_INVESTIGATOR name: Catherine Bollard role: SUB_INVESTIGATOR lat: 38.89511 lon: -77.03637 hasResults: False
nctId: NCT06358625 id: 2023-4-1-001 briefTitle: Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer acronym: CRANIUM overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2031-04-30 date: 2031-04-30 date: 2024-04-10 date: 2024-04-10 name: Center Eugene Marquis class: OTHER briefSummary: HER2 gene amplification, detected in 20% to 30% of breast cancers, was a poor prognostic factor before the advent of anti-HER2 therapies. In the early 2000s, trastuzumab revolutionised the management of patients with HER2-positive (HER2+) breast cancer in the metastatic and localised stages of the disease.
International guidelines do not recommend systematic brain MRI in the absence of neurological symptoms, either in the adjuvant or metastatic stages of this disease. However, there may be a role for more systematic and earlier screening for cerebral recurrence, as single cerebral recurrences without extracranial involvement are common and the new anti-HER2 agents (i.e. tucatinib, an anti-HER2 tyrosine kinase inhibitor, and T-Dxd) have shown significant objective response rates in cerebral metastases.
New tools for these indications would significantly modify our clinical practice, allowing the identification of a subpopulation at high risk of cerebral recurrence, suitable for increased monitoring and therapeutic adjustment. conditions: HER2-positive Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Pre-treatment biopsy measure: Transcriptomic profile change of HER2+ primary breast tumours before any treatment measure: Transcriptomic profile change on circulating tumour DNA (ctDNA) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358612 id: DALNSHA2024ABR001 briefTitle: Evaluation of an Anxiety Reduction Tool During Thyroid and Prostate Biopsy Procedures overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-20 date: 2025-08-31 date: 2024-04-10 date: 2024-04-10 name: Nova Scotia Health Authority class: OTHER briefSummary: Patients undergoing either thyroid or prostate biopsy under local anesthetic will be asked to fill out a questionnaire that evaluates their anxiety level before and after a thyroid or prostate biopsy procedure that they undergo. Patients will be randomly assigned to either use an anxiety reducing tool (stress balls in each hand) to take their mind off the procedure or will not receive an anxiety reducing tool. conditions: Anxiety State studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial primaryPurpose: PREVENTION masking: NONE count: 150 type: ESTIMATED name: Stress Balls name: No Stress Balls measure: Change in anxiety level of greater than 20% based on Visual Analog Score (VAS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358599 id: TUO-UR-21-01 briefTitle: The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy overallStatus: COMPLETED date: 2021-01-07 date: 2023-10-20 date: 2024-01-15 date: 2024-04-10 date: 2024-04-10 name: Ankara Etlik City Hospital class: OTHER_GOV briefSummary: The World Health Organization 2016 bladder tumor classification reported that the diagnosis of variant histology has increased from 6% to 33% in the last 2 decades, and there is an increasing interest in investigating the effects on disease management, treatment options, and survival outcomes in bladder tumors with variant histology. In bladder tumors, variant histology is known to be more aggressive and has a worse prognosis than pure urothelial cancer, and most cases are muscle invasive at diagnosis. Neoadjuvant cisplatin-containing combination chemotherapy is known to improves overall survival in patients with urothelial cancers. However, it is unclear whether patients with non-pure urothelial cancer (variant) histology will also benefit from neoadjuvant chemotherapy. The investigators aimed to evaluate the role of Neoadjuvant cisplatin-containing combination chemotherapy in the final treatment plan and its impact on survival in patients with bladder cancer who were diagnosed with variant histology in the radical cystectomy specimen. conditions: Bladder Cancer conditions: Bladder Cancer Stage I conditions: Bladder Cancer Stage II studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 221 type: ACTUAL name: Cisplatin measure: Change in survival outcomes at postoperative 2-year follow-up in patients with variant histology who received neoadjuvant chemotherapy before radical cystectomy. measure: Factors associated with worse survival outcomes in cox-regression analysis at 2-year follow-up of all patients with variant histology who underwent radical cystectomy. sex: ALL minimumAge: 45 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Etlik City Hospital city: Ankara zip: 06170 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06358586 id: 044(H)MD21176 id: CRO-PK-21-356 type: OTHER domain: CRO code briefTitle: New Paediatric Formulation of Tachipirina® overallStatus: COMPLETED date: 2022-04-09 date: 2022-04-25 date: 2022-04-25 date: 2024-04-10 date: 2024-04-10 name: Aziende Chimiche Riunite Angelini Francesco S.p.A class: INDUSTRY name: Cross S.A. briefSummary: This is a single centre, single dose, single-arm, open-label, palatability study.
The aim of the present study is to investigate the palatability of the newly developed Tachipirina® 120 mg/5 mL oral suspension with strawberry flavour. The study will be conducted in paediatric volunteers that represent the target population for this product. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single centre, single dose, single-arm, open-label, palatability study primaryPurpose: OTHER masking: NONE count: 20 type: ACTUAL name: Tachipirina® 120 mg/5 mL oral suspension, new flavour measure: Palatability of new flavour - Taste (1) measure: Palatability of new flavour - Taste (2) measure: Palatability of new flavour - Smell measure: Palatability of new flavour - Aftertaste (1) measure: Palatability of new flavour - Aftertaste (2) measure: Palatability of new flavour - Aftertaste (3) measure: Palatability of new flavour - Texture (mouthfeel) measure: Palatability of new flavour - Overall measure: Treatment emergent adverse events (TEAEs) sex: ALL minimumAge: 6 Years maximumAge: 17 Years stdAges: CHILD facility: CROSS Research S.A. - Phase I Unit, city: Arzo zip: CH-6864 country: Switzerland lat: 45.87606 lon: 8.94103 hasResults: False
nctId: NCT06358560 id: BrainHealthClinics briefTitle: Applied Clinical Neuroscience and Its Effect on Self-reported Stress and Other Physiological Markers overallStatus: RECRUITING date: 2024-03-04 date: 2024-12-15 date: 2024-12-15 date: 2024-04-10 date: 2024-04-10 name: Dylan Saulsbery class: OTHER briefSummary: The purpose of this study is to see if an applied clinical neuroscience (ACN) approach to the symptom of 'stress' has a measurable effect on an individual's self-reported stress level. Physiological markers will be measured and analyzed to potentially allow for greater insight and aid in setting up any future research on this topic. This is an independent research study. conditions: Stress studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 15 type: ESTIMATED name: Therapeutic exercises measure: NIH Toolbox® Item Bank v3.0 - Perceived Stress (Ages 18+) - Fixed Form sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Brain Health Clinics status: RECRUITING city: Nashville state: Tennessee zip: 37217 country: United States name: Tyler Hurst, DC role: CONTACT phone: 615-922-0977 email: drhurst@thebrainhealthclinics.com name: Dylan Saulsbery, DC role: PRINCIPAL_INVESTIGATOR name: Tyler Hurst, DC role: SUB_INVESTIGATOR name: Dominic Fetterly, DC role: SUB_INVESTIGATOR lat: 36.16589 lon: -86.78444 hasResults: False
nctId: NCT06358547 id: H-23072469 briefTitle: Preimplantation Genetic Testing for Aneuploidy (PGT-A) in Women Aged 37-41 Years overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2028-04-01 date: 2029-04-01 date: 2024-04-10 date: 2024-04-10 name: Rigshospitalet, Denmark class: OTHER briefSummary: A multinational multi-centre, randomized, controlled non-blinded trial with participation of three fertility clinics in Denmark and one in Spain to assess the efficacy and safety of preimplantation genetic testing for aneuploidy (PGT-A) in 37-41-year-old women. conditions: Infertility studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 590 type: ESTIMATED name: PGT-A measure: Live birth rate per first embryo transfer measure: Cumulative live birth rate after one complete ART treatment sex: FEMALE minimumAge: 18 Years maximumAge: 41 Years stdAges: ADULT facility: Rigshospitalet city: København Ø zip: 2100 country: Denmark name: Nathalie F Wang, MD role: CONTACT phone: +4535454071 email: nathalie.friis.wang.03@regionh.dk name: Kristine Løssl, MD role: CONTACT email: kristine.loessl@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06358534 id: RTEU-SBF-KB-01 briefTitle: The Effect of Acceptance and Commitment Therapy in Patients With Chronic Renal Failure overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-01 date: 2023-11-30 date: 2024-07-30 date: 2024-04-10 date: 2024-04-26 name: Recep Tayyip Erdogan University class: OTHER briefSummary: Psychological flexibility, life satisfaction and adaptation to the disease of individuals with chronic kidney disease were increased with psychoeducation based on acceptance and commitment therapy to be given to individuals with chronic kidney disease. conditions: Kidney Failure, Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: pretest-posttest, control and intervention groups primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 32 type: ACTUAL name: psychoeducation based on acceptance and commitment therapy measure: Chronic Disease Adaptation Scale (CHAS): measure: Acceptance and Action Questionnaire-II Scale (AAQ-II) measure: Life Satisfaction Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Recep Tayyip Erdoğan University Faculty of Health Sciences city: Rize state: Güneysu zip: 53100 country: Turkey lat: 41.02083 lon: 40.52194 hasResults: False
nctId: NCT06358508 id: VP-0786 briefTitle: Sapphire 3 CTO Study overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-07 date: 2025-07 date: 2024-04-10 date: 2024-04-15 name: OrbusNeich class: INDUSTRY name: Avania briefSummary: A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device performance of the Sapphire 3 0.85, 1.0 and 1.25mm diameter coronary dilatation catheter in predilatation of Chronic Total Occlusion (CTO) lesions during percutaneous coronary intervention.